Navidea Biopharmaceuticals (NYSEMKT:NAVB) Analyst Rating Consensus

Navidea Biopharmaceuticals (NYSEMKT:NAVB) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 1 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys.

Navidea Biopharmaceuticals (NYSEMKT:NAVB) witnessed a decline in the market cap on Tuesday as its shares dropped 3.56% or 0.0227 points. After the session commenced at $0.6399, the stock reached the higher end at $0.6489 while it hit a low of $0.587. With the volume soaring to 905,420 shares, the last trade was called at $0.6157. The company has a 52-week high of $2.495. The company has a market cap of $96 million and there are 155,612,730 shares in outstanding. The 52-week low of the share price is $0.58.

Navidea Biopharmaceuticals, Inc has lost 2.27% in the last five trading days and dropped 29.23% in the last 4 weeks. Navidea Biopharmaceuticals, Inc has dropped 35.19% during the last 3-month period . Year-to-Date the stock performance stands at -53.71%.

Navidea Biopharmaceuticals, Inc. is a precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. The Company is developing multiple precision-targeted products based on the Manocept platform. The Manocept platform serves as the molecular backbone of Lymphoseek (technetium Tc 99m tilmanocept) injection, the first product developed by the Company based on the platform. Lymphoseek is a receptor-targeted, small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients. NAV4694 is a fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimers disease (AD) and mild cognitive impairment. NAV5001 is an iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinsons disease (PD) and other movement disorders.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.